KRM Ayurveda Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹32Cr
- +36% QoQ
- Net profit
- ₹8Cr
- +87.3% QoQ
- Margin
- 34.09%
- +5.7 pp QoQ
Guidance rank: #2 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
3 of 3 strong
The short version
KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years. KRM Ayurveda Limited expects a minimum of 50% year-on-year revenue growth over the next few years driven by: - Addition of approximately 1,500 to 2,000 beds over the next 3 years.
From KRM Ayurveda Ltd's Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years.
- Growth drivers include adding approximately 1,500 to 2,000 beds over the next three years across India.
- Plans to open around 100 super-specialty clinics within three years, enhancing disease-specific treatments and increasing patient inflow.
- Expansion includes 30 new clinics in the current year and increasing bed capacity from ~235 to 500 beds by year-end.
- Telemedicine expansion with a new 500-seater center to double revenue from products and services.
- Product sales will grow alongside clinic and hospital expansion, supported by e-commerce launches.
2 more points from KRM Ayurveda Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what KRM Ayurveda Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Planning to add approximately 2,000 beds over the next 3-4 years with a cost around ₹2 lakh per bed (Page 24).
- Expansion plans include adding 1500 to 2000 beds pan-India and opening about 100 super-specialty clinics over the next three years (Page 15).
- Expect to increase bed capacity from 235 to 500 beds in FY27, with finalized agreements for additional 100-bed hospital in Gurgaon (Page 15).
- Building a 500-seater telemedicine center operational in 1 to 1.5 years to support expansion (Page 22).
- New luxury hospital of 25 beds being developed in Delhi, with scope for expansion (Page 13).
2 more points from KRM Ayurveda Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what KRM Ayurveda Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what KRM Ayurveda Ltd said on order book & pipeline — free account, 30 seconds.
KRM Ayurveda Ltd — Quarterly revenue & net profit
KRM Ayurveda Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q2 FY26 | QoQ |
|---|---|---|---|
| Revenue | 32 | 24 | +36% |
| Operating profit (EBITDA) | 11 | 7 | +63.2% |
| Operating margin | 34.09% | 28.41% | +5.7 pp |
| Profit before tax | 10 | 6 | +83.3% |
| Net profit (PAT) | 8 | 4 | +87.3% |
| EPS (₹) | 3.67 | 2.69 | +36.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹35 Cr, net profit ₹8 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What KRM Ayurveda's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- 2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
KRM Ayurveda Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were KRM Ayurveda Ltd Q4 FY26 results?
KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years. KRM Ayurveda Limited expects a minimum of 50% year-on-year revenue growth over the next few years driven by: - Addition of approximately 1,500 to 2,000 beds over the next 3 years.
What is KRM Ayurveda Ltd share price analysis?
KRM Ayurveda Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 26.4 with a market cap of ₹664 Cr. Investors should review the full earnings analysis for detailed insights.
Is KRM Ayurveda Ltd planning capital expenditure?
Planning to add approximately 2,000 beds over the next 3-4 years with a cost around ₹2 lakh per bed (Page 24).
Keep KRM Ayurveda Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
